A small clinical trial conducted at WashU Medicine shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Shown, William E. Gillanders, MD, (right) and Xiuli Zhang, MD, examine blood test results indicating study participants' responses to the vaccine. The early-stage trial indicated that the treatment is safe and elicits immune responses.
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by WashU Medicine researchers, the trial is the first to report results for this type of vaccine — known as a neoantigen DNA vaccine — for breast cancer patients.
The study, which found the vaccine to be well-tolerated and to stimulate the immune system, is available Nov. 14 in the journal Genome Medicine.